New FDA Safety Warning for Popular Weight Loss and Diabetes Drugs

The United States Food and Drug Administration (FDA) has taken a new step to protect patients using GLP-1 medications. These drugs, which are widely used for weight loss and type 2 diabetes, must now include a formal warning on their labels about a rare but serious eye condition. This condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It happens when blood flow to the optic nerve is reduced, which can lead to permanent vision loss.

According to MedPage Today, the FDA is requiring all makers of GLP-1 drugs to update their prescribing information. This update follows a series of studies that suggested a possible link between these medications and the eye condition. The agency noted that while NAION is rare, it is important for both doctors and patients to be aware of the potential danger. This action builds on previous safety updates, as the FDA continues to monitor the long-term effects of these popular treatments.

NAION is a condition that often causes sudden, painless vision loss, which many people first notice when they wake up. Other symptoms can include blurred vision, difficulty seeing certain colors, or missing parts of a person's field of vision. Because the condition is serious, the FDA has provided clear instructions for healthcare providers. Doctors should tell their patients to immediately report any sudden changes in their eyesight. If a patient shows signs of NAION, they should be sent to an eye specialist, known as an ophthalmologist, for a full check-up. In some cases, doctors may need to consider stopping the medication if the risks to the patient's vision are greater than the benefits of the drug.

The decision to add this warning comes after a wave of research. MedPage Today reports that a 2024 study in the journal JAMA Ophthalmology involving semaglutide—a common ingredient in drugs like Ozempic and Wegovy—was a major reason for the FDA's review. The agency also performed its own analysis of patient data. In one study of over 134,000 patients, the FDA identified 15 cases of NAION. Ten of these cases were found in patients taking GLP-1 drugs, while none were found in patients taking other types of glucose-lowering medications. The study showed that the rate of this condition was higher among those using GLP-1 drugs compared to those using other treatments or a placebo, which is a substance with no active medicine used for comparison in tests.

It is important to note that the link between these drugs and the eye condition is still being studied. The FDA stated that the exact way these drugs might trigger NAION is not yet fully understood. Furthermore, animal studies did not provide a clear explanation for why the risk might be higher. In a separate study comparing GLP-1 drugs to other diabetes medications, the results were mixed. While there was no significant increase in risk compared to SGLT2 inhibitors, researchers did see a higher risk when comparing GLP-1 drugs to DPP-4 inhibitors.

Patients should also be aware that NAION has several common risk factors. These include smoking, diabetes, high blood pressure, sleep apnea, anemia, and chronic kidney disease. People who have had NAION in the past are also at a higher risk of it happening again. Because of these factors, it is essential for patients to discuss their full medical history with their doctors before starting or continuing any weight loss or diabetes medication.

This is not the first time global health authorities have looked into this issue. MedPage Today noted that drug regulators in Europe issued a warning about this same risk 17 months ago. As more people use these drugs, the FDA continues to encourage both patients and doctors to report any suspected side effects through the agency's MedWatch program. By sharing this information, the medical community can better understand the safety of these treatments and help patients make informed decisions about their health. For now, the main message from the FDA is one of caution: stay aware of your vision and speak with a professional if you notice anything unusual.